 HOUSTON, Sept. 30, 2021 PRNewswire -- CNS Pharmaceuticals, Inc. NASDAQ: CNSP CNS or the Company, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme GBM, one of the most aggressive types of brain cancer. 